Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.58 |
| ▸ | PARP1 | P09874 | 6/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | PARP11 | Q9NR21 | 8/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | PRF1 | P14222 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386434 | 0.88 | PARP11 (0.61) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL20625609 | 0.84 | CLK4 (0.47) | PARP10PARP1F7F3PIM1 | |
| SCHEMBL8255407 | 0.83 | PARP10 (0.59) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL8162850 | 0.83 | PARP10 (0.63) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL22995086 | 0.80 | PARP10 (0.63) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL14984344 | 0.80 | PARP10 (0.58) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL8190887 | 0.79 | PARP10 (0.58) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL23397539 | 0.78 | PBRM1 (0.49) | — | |
| SCHEMBL25780903 | 0.78 | SMN1; SMN2 (0.43) | PARP10PARP1PARP11 | |
| SCHEMBL12459041 | 0.76 | PARP10 (0.71) | PARP10PARP1F7F3PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | PARP10 1170/4885PARP1 626/4885F7 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.